Perceptive Advisors LLC raised its stake in Wave Life Sciences Ltd (NASDAQ:WVE) by 3.1% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 662,798 shares of the company’s stock after purchasing an additional 20,000 shares during the period. Perceptive Advisors LLC owned about 2.39% of Wave Life Sciences worth $23,264,000 as of its most recent filing with the Securities and Exchange Commission (SEC).
A number of other hedge funds also recently bought and sold shares of the business. BlackRock Inc. raised its position in Wave Life Sciences by 60.0% in the 4th quarter. BlackRock Inc. now owns 934,733 shares of the company’s stock valued at $32,810,000 after purchasing an additional 350,570 shares in the last quarter. Point72 Asset Management L.P. acquired a new stake in Wave Life Sciences in the 3rd quarter valued at about $13,679,000. Vanguard Group Inc. raised its position in Wave Life Sciences by 40.3% in the 2nd quarter. Vanguard Group Inc. now owns 215,691 shares of the company’s stock valued at $4,012,000 after purchasing an additional 61,910 shares in the last quarter. Northern Trust Corp raised its position in Wave Life Sciences by 66.3% in the 2nd quarter. Northern Trust Corp now owns 165,794 shares of the company’s stock valued at $3,085,000 after purchasing an additional 66,120 shares in the last quarter. Finally, State Street Corp raised its position in Wave Life Sciences by 26.6% in the 2nd quarter. State Street Corp now owns 151,241 shares of the company’s stock valued at $2,815,000 after purchasing an additional 31,743 shares in the last quarter. 79.66% of the stock is currently owned by institutional investors.
Several equities research analysts have recently weighed in on the company. Zacks Investment Research lowered Wave Life Sciences from a “hold” rating to a “sell” rating in a research report on Saturday, January 13th. Leerink Swann reissued an “outperform” rating and set a $53.00 target price (up previously from $42.00) on shares of Wave Life Sciences in a research report on Wednesday, November 15th. BidaskClub raised Wave Life Sciences from a “sell” rating to a “hold” rating in a research report on Tuesday, November 14th. SunTrust Banks raised their target price on Wave Life Sciences to $60.00 and gave the stock a “buy” rating in a research report on Friday. Finally, Mizuho set a $34.00 target price on Wave Life Sciences and gave the stock a “buy” rating in a research report on Tuesday, February 20th. Two research analysts have rated the stock with a sell rating and seven have issued a buy rating to the stock. Wave Life Sciences has an average rating of “Buy” and a consensus price target of $47.60.
Shares of Wave Life Sciences Ltd (NASDAQ:WVE) opened at $47.00 on Monday. The company has a current ratio of 11.50, a quick ratio of 11.50 and a debt-to-equity ratio of 0.01. Wave Life Sciences Ltd has a 12-month low of $15.15 and a 12-month high of $55.95.
Wave Life Sciences Profile
WAVE Life Sciences Ltd. is a genetic medicines company. The Company, through its synthetic chemistry drug development platform, designs, develops and commercializes a pipeline of nucleic acid therapeutic candidates for genetically defined diseases. The Company is engaged in developing oligonucleotides that target genetic defects to either reduce the expression of disease-promoting proteins or transform the production of dysfunctional mutant proteins into the production of functional proteins.
Want to see what other hedge funds are holding WVE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Wave Life Sciences Ltd (NASDAQ:WVE).
Receive News & Ratings for Wave Life Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Wave Life Sciences and related companies with MarketBeat.com's FREE daily email newsletter.